Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of spesolimab in moderate to severe atopic dermatitis
jRCT2080224704Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Spesolimab arm with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in EASI score at week 16. Started May 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224704.